| 1 |
34765562 | Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells. | 2021 |
1 |
| 2 |
27935859 | Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. | 2017 Jan 31 |
3 |
| 3 |
28537899 | NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. | 2017 Jul 11 |
3 |
| 4 |
26640145 | MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas. | 2016 Jul 14 |
4 |
| 5 |
26811014 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. | 2016 Mar |
1 |
| 6 |
26848526 | Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. | 2016 Mar 1 |
2 |
| 7 |
24806744 | Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. | 2015 Jan |
3 |
| 8 |
24850846 | Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients. | 2014 Jul 15 |
1 |
| 9 |
23820962 | Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. | 2013 Sep |
3 |
| 10 |
22189940 | Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma. | 2012 Feb |
1 |
| 11 |
22416775 | HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. | 2012 Mar |
1 |
| 12 |
22506596 | Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. | 2012 Oct |
2 |
| 13 |
22551975 | Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. | 2012 Sep |
4 |
| 14 |
22825908 | QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. | 2012 |
2 |
| 15 |
23141799 | HDAC inhibitor-based therapies: can we interpret the code? | 2012 Dec |
2 |
| 16 |
21110829 | Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. | 2011 Jan |
1 |
| 17 |
21198545 | The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. | 2011 Apr |
1 |
| 18 |
21591544 | Therapeutic advances in cutaneous T-cell lymphoma. | 2011 Feb |
1 |
| 19 |
21879444 | The biology of HDAC in cancer: the nuclear and epigenetic components. | 2011 |
2 |
| 20 |
19817748 | Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. | 2010 Jan |
4 |
| 21 |
20127862 | Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. | 2010 Nov 1 |
1 |
| 22 |
20132536 | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. | 2010 Feb 4 |
1 |
| 23 |
20371442 | The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. | 2010 Apr |
1 |
| 24 |
20479100 | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. | 2010 May 15 |
4 |
| 25 |
21132350 | Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. | 2010 Dec |
1 |
| 26 |
19362413 | Biomarkers for predicting clinical responses to HDAC inhibitors. | 2009 Aug 8 |
2 |
| 27 |
19951879 | Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. | 2009 Dec |
2 |
| 28 |
18483262 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. | 2008 May 15 |
4 |
| 29 |
18628067 | Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. | 2008 Jul |
3 |
| 30 |
18665425 | FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. | 2008 Nov-Dec |
1 |
| 31 |
16960145 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). | 2007 Jan 1 |
2 |
| 32 |
17109024 | Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? | 2007 Jan |
2 |
| 33 |
17438089 | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. | 2007 Apr 15 |
3 |
| 34 |
17594194 | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. | 2007 Jul |
3 |
| 35 |
17763605 | A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. | 2007 Jul |
2 |
| 36 |
17940636 | Vorinostat in cutaneous T-cell lymphoma. | 2007 Sep |
2 |
| 37 |
19707308 | Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. | 2007 Dec |
4 |
| 38 |
17286158 | Treatment of cutaneous T-cell lymphoma/mycosis fungoides. | 2006 Dec |
2 |